NECAB1 and temporal lobe epilepsy: In order to examine whether the expression levels of NECAB1, PV, and CR are influenced by circuit reorganization caused by temporal lobe epilepsy and how novel antiseizure medication modulates these changes, we first quantified NECAB1-immunopositive neuron cell bodies across distinct brain regions, including the amygdala, endopiriform nucleus, and the paraventricular nucleus of the thalamus and the hippocampus (CA1, CA2–CA3, and dentate gyrus; see Figure 2).